{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:37:12Z","timestamp":1790660232146,"version":"4.1.0"},"reference-count":39,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["The University of Texas M.D. Anderson Cancer Cente"],"award-info":[{"award-number":["The University of Texas M.D. Anderson Cancer Cente"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Genitourinary Cancers Program of the Cancer Center Support Grant","award":["The University of Texas M.D. Anderson Cancer Cente"],"award-info":[{"award-number":["The University of Texas M.D. Anderson Cancer Cente"]}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","award":["D2018-014"],"award-info":[{"award-number":["D2018-014"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The University of Texas MD Anderson Cancer Center Prostate Cancer Moon Shot Program","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2023,2,8]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The prostate tumor microenvironment (TME) is immunosuppressive, with few effector T cells and enrichment of inhibitory immune populations, leading to limited responses to treatments such as immune checkpoint therapies (ICTs). The immune composition of the prostate TME differs across soft tissue and bone, the most common site of treatment-refractory metastasis. Understanding immunosuppressive mechanisms specific to prostate TMEs will enable rational immunotherapy strategies to generate effective antitumor immune responses. Daratumumab (anti-CD38 antibody) and edicotinib (colony-stimulating factor-1 receptor (CSF-1R) inhibitor) may alter the balance within the prostate TME to promote antitumor immune responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Daratumumab or edicotinib will be safe and will alter the immune TME, leading to antitumor responses in localized prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In this presurgical study, patients with localized prostate cancer received 4 weekly doses of daratumumab or 4 weeks of daily edicotinib prior to radical prostatectomy (RP). Treated and untreated control (Gleason score \u22658 in prostate biopsy) prostatectomy specimens and patient-matched pre- and post-treatment peripheral blood mononuclear cells (PBMCs) and bone marrow samples were evaluated. The primary endpoint was incidence of adverse events (AEs). The secondary endpoint was pathologic complete remission (pCR) rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-five patients were treated (daratumumab, n=15; edicotinib, n=10). All patients underwent RP without delays. Grade 3 treatment-related AEs with daratumumab occurred in 3 patients (12%), and no \u2265grade 3 treatment-related AEs occurred with edicotinib. No changes in serum prostate-specific antigen (PSA) levels or pCRs were observed. Daratumumab led to a decreased frequency of CD38\n                      <jats:sup>+<\/jats:sup>\n                      T cells, natural killer cells, and myeloid cells in prostate tumors, bone marrow, and PBMCs. There were no consistent changes in CSF-1R\n                      <jats:sup>+<\/jats:sup>\n                      immune cells in prostate, bone marrow, or PBMCs with edicotinib. Neither treatment induced T cell infiltration into the prostate TME.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Daratumumab and edicotinib treatment was safe and well-tolerated in patients with localized prostate cancer but did not induce pCRs. Decreases in CD38\n                      <jats:sup>+<\/jats:sup>\n                      immune cells were observed in prostate tumors, bone marrow, and PBMCs with daratumumab, but changes in CSF-1R\n                      <jats:sup>+<\/jats:sup>\n                      immune cells were not consistently observed with edicotinib. Neither myeloid-targeted agent alone was sufficient to generate antitumor responses in prostate cancer; thus, combinations with agents to induce T cell infiltration (eg, ICTs) will be needed to overcome the immunosuppressive prostate TME.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2022-006262","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T10:32:04Z","timestamp":1679481124000},"page":"e006262","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03177460","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03473730","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-1294","authenticated-orcid":false,"given":"Bilal A","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F","family":"Chapin","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Jindal","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Duan","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-3833","authenticated-orcid":false,"given":"Sreyashi","family":"Basu","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini S","family":"Yadav","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Di","family":"Gu","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8841-7219","authenticated-orcid":false,"given":"Alexsandra B","family":"Espejo","sequence":"additional","affiliation":[{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Kinder","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A","family":"Pettaway","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-8582","authenticated-orcid":false,"given":"Rebecca S S","family":"Tidwell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Troncoso","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G","family":"Corn","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Logothetis","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Knoblauch","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hutnick","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gottardis","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles G","family":"Drake","sequence":"additional","affiliation":[{"name":"Janssen Research & Development, Spring House, Pennsylvania, USA"},{"name":"Department of Medicine, Columbia University Medical Center, New York, New York, USA"},{"name":"Department of Urology, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmanee","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"The Immunotherapy Platform, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit K","family":"Subudhi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2025100303261482000_11.3.e006262.1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025100303261482000_11.3.e006262.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"2025100303261482000_11.3.e006262.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature21676"},{"key":"2025100303261482000_11.3.e006262.4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100303261482000_11.3.e006262.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0569"},{"key":"2025100303261482000_11.3.e006262.6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"2025100303261482000_11.3.e006262.7","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4308"},{"key":"2025100303261482000_11.3.e006262.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.10.029"},{"key":"2025100303261482000_11.3.e006262.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002919","article-title":"Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment","volume":"9","author":"Subudhi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100303261482000_11.3.e006262.10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett"},{"key":"2025100303261482000_11.3.e006262.11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.597959","article-title":"Cd38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"2025100303261482000_11.3.e006262.12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.129","article-title":"Adenosine receptor blockade with ciforadenant +\/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mcrpc)","volume":"38","author":"Harshman","year":"2020","journal-title":"JCO"},{"key":"2025100303261482000_11.3.e006262.13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5039","article-title":"ARC-6: a phase 1b\/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928) -based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mcrpc)","volume":"39","author":"Subudhi","year":"2021","journal-title":"JCO"},{"key":"2025100303261482000_11.3.e006262.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00466-6"},{"key":"2025100303261482000_11.3.e006262.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"2025100303261482000_11.3.e006262.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2027"},{"key":"2025100303261482000_11.3.e006262.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11053-8","article-title":"Deletion of a CSF1R enhancer selectively impacts CSF1R expression and development of tissue macrophage populations","volume":"10","author":"Rojo","year":"2019","journal-title":"Nat Commun"},{"key":"2025100303261482000_11.3.e006262.18","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1795-1807.2001"},{"key":"2025100303261482000_11.3.e006262.19","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025100303261482000_11.3.e006262.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.10.005"},{"key":"2025100303261482000_11.3.e006262.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1845"},{"key":"2025100303261482000_11.3.e006262.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"2025100303261482000_11.3.e006262.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"2025100303261482000_11.3.e006262.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"2025100303261482000_11.3.e006262.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140404"},{"key":"2025100303261482000_11.3.e006262.26","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L"},{"key":"2025100303261482000_11.3.e006262.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0173"},{"key":"2025100303261482000_11.3.e006262.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025100303261482000_11.3.e006262.29","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and sirius trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025100303261482000_11.3.e006262.30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"2025100303261482000_11.3.e006262.31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.eururo.2021.01.017","article-title":"Cd38 in advanced prostate cancers","volume":"79","author":"Guo","year":"2021","journal-title":"Eur Urol"},{"key":"2025100303261482000_11.3.e006262.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0266-0"},{"key":"2025100303261482000_11.3.e006262.33","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00262-015-1752-y","article-title":"Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression","volume":"64","author":"Japp","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2025100303261482000_11.3.e006262.34","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025100303261482000_11.3.e006262.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141580"},{"key":"2025100303261482000_11.3.e006262.36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.36401\/JIPO-20-32","article-title":"Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors","volume":"4","author":"Lin","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"2025100303261482000_11.3.e006262.37","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0855"},{"key":"2025100303261482000_11.3.e006262.38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41577-022-00737-w","article-title":"Myeloid cell-targeted therapies for solid tumours","volume":"23","author":"Goswami","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025100303261482000_11.3.e006262.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.048"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-006262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:26:27Z","timestamp":1759487187000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/jitc-2022-006262"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-006262","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}